Los Angeles Capital Management LLC Sells 63,407 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Los Angeles Capital Management LLC trimmed its position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 18.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 271,262 shares of the biotechnology company’s stock after selling 63,407 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.46% of Aldeyra Therapeutics worth $1,462,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Acadian Asset Management LLC lifted its position in Aldeyra Therapeutics by 106.3% during the 1st quarter. Acadian Asset Management LLC now owns 452,449 shares of the biotechnology company’s stock worth $1,478,000 after buying an additional 233,169 shares in the last quarter. Diversified Trust Co bought a new stake in shares of Aldeyra Therapeutics during the second quarter valued at approximately $41,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Aldeyra Therapeutics in the first quarter valued at approximately $585,000. Federated Hermes Inc. bought a new position in Aldeyra Therapeutics in the 2nd quarter worth approximately $1,758,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Aldeyra Therapeutics by 7.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 48,273 shares of the biotechnology company’s stock worth $158,000 after buying an additional 3,446 shares in the last quarter. Institutional investors and hedge funds own 59.71% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a research note on Friday, August 9th.

Aldeyra Therapeutics Trading Down 3.2 %

Shares of NASDAQ ALDX opened at $4.27 on Friday. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18. The firm’s 50-day moving average is $5.53 and its 200-day moving average is $4.60. Aldeyra Therapeutics, Inc has a 1 year low of $2.43 and a 1 year high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.25). Equities analysts expect that Aldeyra Therapeutics, Inc will post -0.48 EPS for the current year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.